Comment: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.
Brittany D BissellBreanne M MeffordJ Chris DonaldsonPublished in: The Annals of pharmacotherapy (2021)
Keyphrases
- high dose
- low dose
- respiratory failure
- end stage renal disease
- coronavirus disease
- sars cov
- ejection fraction
- newly diagnosed
- chronic kidney disease
- rheumatoid arthritis
- extracorporeal membrane oxygenation
- stem cell transplantation
- prognostic factors
- mechanical ventilation
- peritoneal dialysis
- type diabetes
- systemic lupus erythematosus
- patient reported outcomes
- acute respiratory distress syndrome